NasdaqGS - Nasdaq Real Time Price USD

Viatris Inc. (VTRS)

11.44 +0.09 (+0.75%)
As of 2:07 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Scott Andrew Smith CEO & Director -- -- 1962

Viatris Inc.

1000 Mylan Boulevard
Canonsburg, PA 15317
United States
724 514 1800 https://www.viatris.com
Sector: 
Healthcare
Full Time Employees: 
38,000

Description

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Corporate Governance

Viatris Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 7; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Mar 18, 2024
    Dividend Date
  • Mar 08, 2024
    Ex-Dividend Date
  • Feb 28, 2024
    10-K: Periodic Financial Reports
    See Full Filing
  • Jan 30, 2024
    8-K/A: Corporate Changes & Voting Matters
    See Full Filing
  • Jan 26, 2024
    SC 13G/A: Tender Offer/Acquisition Reports
    See Full Filing

Upcoming Events

May 06, 2024 - May 10, 2024
Viatris Inc. Earnings Call

Related Tickers

TEVA Teva Pharmaceutical Industries Limited
12.98
-0.23%
 
HLN Haleon plc
8.34
-0.89%
 
ELAN Elanco Animal Health Incorporated
13.36
-0.78%
 
TAK Takeda Pharmaceutical Company Limited
13.27
-0.86%
 
ZTS Zoetis Inc.
150.90
+0.90%
 
BHC Bausch Health Companies Inc.
8.55
+0.18%
 
ESPR Esperion Therapeutics, Inc.
2.1250
+1.67%
 
EOLS Evolus, Inc.
11.52
-1.54%
 
DCPH Deciphera Pharmaceuticals, Inc.
14.70
+0.20%
 
DVAX Dynavax Technologies Corporation
11.40
-3.06%